



Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society

CAMBRIDGE, MA, September 28, 2017 – [Catabasis Pharmaceuticals, Inc.](http://www.catabasis.com) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will present data from the Catabasis and Sarepta joint research collaboration in Duchenne muscular dystrophy (DMD) at the 22nd International Congress of the World Muscle Society in a poster presentation titled “Edasalonexent (CAT-1004), an NF-κB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice” during poster session 4 on Thursday, October 5, 2017 from 17:00 – 18:30 CEST. The International Congress of the World Muscle Society is being held October 3 – 7, 2017, at the Palais du Grand Large in Saint Malo, France.

About Edasalonexent

Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-κB, a protein that is activated in DMD and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. We are currently conducting the MoveDMD trial, a three-part clinical trial investigating the safety and efficacy of edasalonexent in boys enrolled at ages 4 – 7 affected with DMD (any confirmed mutation). The third part of the trial, an open-label extension with edasalonexent, is ongoing. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

###

Investor and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

amatthews@catabasis.com